BRIACELL THERAPEUTICS CORP. Foreign Currency Transaction Gain (Loss), before Tax
BRIACELL THERAPEUTICS CORP. (BCTX) reported Foreign Currency Transaction Gain (Loss), before Tax of -$2.62 thousand for the 3-month period ending 2026-04-30, per its 10-Q filed 2026-06-09.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-06-09
- BRIACELL THERAPEUTICS CORP. foreign currency transaction gain (loss), before tax for the quarter ending 2026-04-30 was -$2.62K, a 547.69% decline year-over-year.
- BRIACELL THERAPEUTICS CORP. foreign currency transaction gain (loss), before tax for the quarter ending 2026-01-31 was -$21.05K, a 202.55% decline year-over-year.
- BRIACELL THERAPEUTICS CORP. foreign currency transaction gain (loss), before tax for the quarter ending 2025-10-31 was $20.68K.
- BRIACELL THERAPEUTICS CORP. foreign currency transaction gain (loss), before tax for the quarter ending 2025-07-31 was -$44.72K.
- BRIACELL THERAPEUTICS CORP. foreign currency transaction gain (loss), before tax for fiscal 2025 was -$24.94K.
- BRIACELL THERAPEUTICS CORP. foreign currency transaction gain (loss), before tax for fiscal 2024 was -$25.45K.
- BRIACELL THERAPEUTICS CORP. foreign currency transaction gain (loss), before tax for fiscal 2023 was -$40.87K.
- BRIACELL THERAPEUTICS CORP. foreign currency transaction gain (loss), before tax for fiscal 2022 was -$30.73K.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2026-04-30 | -$2.62K 10-Q · filed 2026-06-09 | -$23.67K derived: sum of 2 quarters · filed 2026-06-09 | -$2.99K 10-Q · filed 2026-06-09 | -$47.71K derived: sum of 4 quarters · filed 2026-06-09 |
| 2026-01-31 | -$21.05K 10-Q · filed 2026-03-10 | -$372.00 10-Q · filed 2026-03-10 | -$45.09K derived: sum of 3 quarters · filed 2026-03-10 | -$44.50K derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-10-31 | $20.68K 10-Q · filed 2025-12-11 | -$24.04K derived: sum of 2 quarters · filed 2025-12-11 | -$23.45K derived: sum of 3 quarters · filed 2026-06-09 | -$2.93K derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-07-31 | -$44.72K derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | -$44.13K derived: sum of 2 quarters · filed 2026-06-09 | -$23.61K derived: sum of 3 quarters · filed 2026-06-09 | -$24.94K 10-K · filed 2025-10-16 |
| 2025-04-30 | $585.00 10-Q · filed 2026-06-09 | $21.11K derived: sum of 2 quarters · filed 2026-06-09 | $19.77K 10-Q · filed 2026-06-09 | $7.67K derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-01-31 | $20.53K 10-Q · filed 2026-03-10 | $19.19K 10-Q · filed 2026-03-10 | $7.09K derived: sum of 3 quarters · filed 2026-03-10 | $4.70K derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-10-31 | -$1.34K 10-Q · filed 2025-12-11 | -$13.44K derived: sum of 2 quarters · filed 2025-12-11 | -$15.83K derived: sum of 3 quarters · filed 2025-12-11 | -$15.79K derived: sum of 4 quarters · filed 2025-12-11 |
| 2024-07-31 | -$12.10K derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | -$14.49K derived: sum of 2 quarters · filed 2025-10-16 | -$14.46K derived: sum of 3 quarters · filed 2025-10-16 | -$25.45K 10-K · filed 2025-10-16 |
| 2024-04-30 | -$2.39K 10-Q · filed 2025-06-16 | -$2.36K derived: sum of 2 quarters · filed 2025-06-16 | -$13.35K 10-Q · filed 2025-06-16 | -$26.84K derived: sum of 4 quarters · filed 2025-06-16 |
| 2024-01-31 | $33.00 10-Q · filed 2025-03-12 | -$10.96K 10-Q · filed 2025-03-12 | -$24.45K derived: sum of 3 quarters · filed 2025-03-12 | -$35.77K derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-10-31 | -$10.99K 10-Q · filed 2024-12-16 | -$24.48K derived: sum of 2 quarters · filed 2024-12-16 | -$35.80K derived: sum of 3 quarters · filed 2024-12-16 | -$42.33K derived: sum of 4 quarters · filed 2024-12-16 |
| 2023-07-31 | -$13.48K derived: 10-K 12 month − 10-Q 9 month · filed 2024-10-29 | -$24.81K derived: sum of 2 quarters · filed 2024-10-29 | -$31.34K derived: sum of 3 quarters · filed 2024-10-29 | -$40.87K 10-K · filed 2024-10-29 |
| 2023-04-30 | -$11.32K 10-Q · filed 2024-06-14 | -$17.86K derived: sum of 2 quarters · filed 2024-06-14 | -$27.39K 10-Q · filed 2024-06-14 | -$52.34K derived: sum of 4 quarters · filed 2024-06-14 |
| 2023-01-31 | -$6.53K 10-Q · filed 2024-03-18 | -$16.07K 10-Q · filed 2024-03-18 | -$41.02K derived: sum of 3 quarters · filed 2024-03-18 | -$40.79K derived: sum of 4 quarters · filed 2024-03-18 |
| 2022-10-31 | -$9.53K 10-Q · filed 2023-12-14 | -$34.48K derived: sum of 2 quarters · filed 2023-12-14 | -$34.26K derived: sum of 3 quarters · filed 2023-12-14 | -$40.30K derived: sum of 4 quarters · filed 2023-12-14 |
| 2022-07-31 | -$24.95K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-25 | -$24.72K derived: sum of 2 quarters · filed 2023-10-25 | -$30.76K derived: sum of 3 quarters · filed 2023-10-25 | -$30.73K 10-K · filed 2023-10-25 |
| 2022-04-30 | $228.00 10-Q · filed 2023-06-14 | -$5.81K derived: sum of 2 quarters · filed 2023-06-14 | -$5.78K 10-Q · filed 2023-06-14 | |
| 2022-01-31 | -$6.04K 10-Q · filed 2023-03-16 | -$6.01K 10-Q · filed 2023-03-16 | ||
| 2021-10-31 | $34.00 10-Q · filed 2022-12-14 | |||
| 2021-07-31 | -$2.18M 10-K · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |